开云app官网登录入口网页版-官方正版

#ALA#

79篇内容 | 1821人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2077099, encodeId=a67520e709961, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=α硫辛酸(ALA)、硝苯地平和格列美脲联合治疗糖尿病视网膜病变的日疗效, objectType=article, longId=739766, objectId=3118e39766e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3118e39766e1, replyNumber=0, likeNumber=80, createdTime=2023-05-10, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3118e39766e1, moduleTitle=α硫辛酸(ALA)、硝苯地平和格列美脲联合治疗糖尿病视网膜病变的日疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3118e39766e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077097, encodeId=36d120e709750, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究, objectType=article, longId=728258, objectId=3b8ae28258e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b8ae28258e7, replyNumber=0, likeNumber=93, createdTime=2023-01-11, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b8ae28258e7, moduleTitle=2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3b8ae28258e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077096, encodeId=2c1620e7096b6, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, objectType=article, longId=295681, objectId=0b9e295681bd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b9e295681bd, replyNumber=0, likeNumber=80, createdTime=2022-04-26, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b9e295681bd, moduleTitle=Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=0b9e295681bd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077098, encodeId=097320e709848, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌, objectType=article, longId=736915, objectId=4bffe369156f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4bffe369156f, replyNumber=0, likeNumber=104, createdTime=2023-01-28, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4bffe369156f, moduleTitle=Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4bffe369156f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077087, encodeId=888f20e708702, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性, objectType=article, longId=214106, objectId=eb67214106de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eb67214106de, replyNumber=0, likeNumber=91, createdTime=2022-03-30, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eb67214106de, moduleTitle=J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=eb67214106de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077089, encodeId=35d820e7089b0, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=FDA：GSK的Nucala（美泊利单抗）获批用于治疗慢性鼻窦炎鼻息肉, objectType=article, longId=215174, objectId=6ecc2151e40e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ecc2151e40e, replyNumber=0, likeNumber=111, createdTime=2022-02-21, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ecc2151e40e, moduleTitle=FDA：GSK的Nucala（美泊利单抗）获批用于治疗慢性鼻窦炎鼻息肉, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6ecc2151e40e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077092, encodeId=e4c220e7092a3, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！, objectType=article, longId=217212, objectId=a44c21e21243, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a44c21e21243, replyNumber=0, likeNumber=82, createdTime=2021-12-31, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a44c21e21243, moduleTitle=Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=a44c21e21243)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077091, encodeId=e4d420e7091e9, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤, objectType=article, longId=216637, objectId=99fe21663e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=99fe21663e10, replyNumber=0, likeNumber=92, createdTime=2022-06-11, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=99fe21663e10, moduleTitle=Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=99fe21663e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077095, encodeId=234720e709521, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌 , objectType=article, longId=221637, objectId=357d22163ea7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=357d22163ea7, replyNumber=0, likeNumber=75, createdTime=2022-08-02, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=357d22163ea7, moduleTitle=Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌 , moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=357d22163ea7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077088, encodeId=7bda20e70880a, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！, objectType=article, longId=214991, objectId=9fdb214991ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9fdb214991ba, replyNumber=0, likeNumber=76, createdTime=2021-12-28, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9fdb214991ba, moduleTitle=J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=9fdb214991ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077094, encodeId=6a2720e709426, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性, objectType=article, longId=218921, objectId=017b21892120, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=017b21892120, replyNumber=0, likeNumber=79, createdTime=2022-05-31, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=017b21892120, moduleTitle=J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=017b21892120)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077090, encodeId=71af20e709029, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, objectType=article, longId=215592, objectId=aefb21559219, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aefb21559219, replyNumber=0, likeNumber=63, createdTime=2021-09-17, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aefb21559219, moduleTitle=Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aefb21559219)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077093, encodeId=547a20e709340, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, objectType=article, longId=217525, objectId=c79c21e52563, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c79c21e52563, replyNumber=0, likeNumber=65, createdTime=2022-03-15, rootId=0, userName=hb2008ye, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c79c21e52563, moduleTitle=Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c79c21e52563)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077086, encodeId=f1ea20e7086ca, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病, objectType=article, longId=204332, objectId=25ac2043325e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25ac2043325e, replyNumber=0, likeNumber=74, createdTime=2021-10-03, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25ac2043325e, moduleTitle=NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=25ac2043325e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077079, encodeId=e9ac20e7079e3, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Cephalalgia：无创迷走神经刺激在急性和发作性慢性丛集性头痛中的不同疗效, objectType=article, longId=190024, objectId=6db719002493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6db719002493, replyNumber=0, likeNumber=68, createdTime=2020-05-09, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6db719002493, moduleTitle=Cephalalgia：无创迷走神经刺激在急性和发作性慢性丛集性头痛中的不同疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6db719002493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077080, encodeId=bf8520e708049, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效, objectType=article, longId=190747, objectId=c318190e4795, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c318190e4795, replyNumber=0, likeNumber=73, createdTime=2020-04-29, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c318190e4795, moduleTitle=Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c318190e4795)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077082, encodeId=764c20e70820a, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果, objectType=article, longId=191477, objectId=26091914e7bf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=26091914e7bf, replyNumber=0, likeNumber=90, createdTime=2020-09-04, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=26091914e7bf, moduleTitle=IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=26091914e7bf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077084, encodeId=622420e7084c7, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, objectType=article, longId=196009, objectId=77a7196009ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77a7196009ec, replyNumber=0, likeNumber=87, createdTime=2020-07-04, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77a7196009ec, moduleTitle=Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=77a7196009ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077076, encodeId=e80020e70766f, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL, objectType=article, longId=185326, objectId=ed2f185326f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ed2f185326f5, replyNumber=0, likeNumber=83, createdTime=2020-02-04, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ed2f185326f5, moduleTitle=Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ed2f185326f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2077085, encodeId=fc0b20e7085fd, content=<a href='/topic/show?id=955d226045' target=_blank style='color:#2F92EE;'>#ALA#</a>, objectTitle=FDA批准Nucala在美国治疗高嗜酸性粒细胞综合征（HES）, objectType=article, longId=201248, objectId=3a65201248f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a65201248f1, replyNumber=0, likeNumber=76, createdTime=2021-02-08, rootId=0, userName=ms55066533437992, userId=b5132500067, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a65201248f1, moduleTitle=FDA批准Nucala在美国治疗高嗜酸性粒细胞综合征（HES）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3a65201248f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

ALA

2020-05-29

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

α硫辛酸(ALA)、硝苯地平和格列美脲联合治疗糖尿病视网膜病变的日疗效

2023-05-10

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

2022 ASCO：对复发性或难治性广泛期小细胞肺癌患者连续服用他拉唑帕尼（TALA）加间歇性低剂量替莫唑胺（TMZ）的2期研究

2023-01-11

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Ann Oncol：Ceralasertib (AZD6738)联合durvalumab（德瓦鲁单抗）治疗抗PD-1失败晚期/转移性黑色素瘤患者的疗效

2022-04-26

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Avelumab与Talazoparib联合治疗有望用于复发性 pMMR 子宫内膜癌

2023-01-28

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

J Clin Oncol：Pegaspargase和Calaspargase Pegol治疗儿童ALL的疗效和毒性

2022-03-30

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

FDA：GSK的Nucala（美泊利单抗）获批用于治疗慢性鼻窦炎鼻息肉

2022-02-21

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Lancet Oncol：慢性淋巴细胞白血病三联一线疗法：Acalabrutinib+Venetoclax+Obinutuzumab！

2021-12-31

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Clin Cancer Res：Ceralasertib(AZD6738)联合紫杉醇或可有效治疗PD1/L1耐药性黑色素瘤

2022-06-11

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Clin Cancer Res：派姆单抗联合Acalabrutinib治疗复发/转移性头颈鳞状细胞癌

2022-08-02

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

J Clin Oncol：Acalabrutinib和依鲁替尼用于CLL的长期疗效PK！

2021-12-28

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

J Dermatolog Treat：Dermalax TM DEEP用于矫正中度至重度鼻唇沟的疗效和安全性

2022-05-31

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Lancet Oncol：PARP抑制剂Talazoparib在晚期转移性去势抵抗性前列腺癌中的抗肿瘤活性

2021-09-17

hb2008ye (审核中...)

前往app查看评论内容

#ALA#

Clin Cancer Res：III期临床研究NALA（来那替尼+卡培他滨 vs 拉帕替尼+卡培他滨）的标志物探索

2022-03-15

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

NICE支持Calquence（acalabrutinib）治疗慢性淋巴细胞白血病

2021-10-03

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Cephalalgia：无创迷走神经刺激在急性和发作性慢性丛集性头痛中的不同疗效

2020-05-09

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Blood：选择性BTK抑制剂acalabrutinib治疗慢淋白血病的事宜剂量及疗效

2020-04-29

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

IL-5拮抗剂Nucala治疗慢性鼻-鼻窦炎的临床试验：取得阳性结果

2020-09-04

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Truxima、来那度胺和acalabrutinib方案治疗复发难治性侵袭性B细胞淋巴瘤：安全有效

2020-07-04

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

Blood：BTK抑制剂acalabrutinib治疗复发性/难治性CLL/SLL

2020-02-04

ms55066533437992 (审核中...)

前往app查看评论内容

#ALA#

FDA批准Nucala在美国治疗高嗜酸性粒细胞综合征（HES）

2021-02-08

科室
- - 订阅+
  - 更多科室
工具
服务